Company intelligence / Profile preview

Nazami BioProducts

Westlake Village, California, USA

Ownership: Private
Development stage: Other

Overview

Nazami BioProducts is a clinical-stage biotechnology company focused on the development of targeted therapies for oncology and infectious diseases. The company leverages its proprietary Molecular Targeted Therapy (MTT) platform to create precision medicines that aim to improve efficacy and reduce toxicity compared to conventional treatments. Its lead oncology candidate, NZM-101, is designed to target metabolic vulnerabilities in cancer cells, while its antiviral candidate, NZM-401, has been evaluated in clinical trials for the treatment of COVID-19. Headquartered in California, Nazami BioProducts continues to advance its pipeline through internal research and strategic clinical development.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeTargeted therapy
Industry: Biotech

Beyond the preview

Go deeper on Nazami BioProducts.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nazami BioProducts.

Explore the full profile